Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.

NDAQ:AUPH - Post by User

Aurinia Pharmaceuticals Inc

Bullboard Posts

Post by MarineJumperon Jan 17, 2020 8:30pm

483 Views

Post# 30567659

If you like similar multi-baggers

I have been in AUP since $5.00 and I have posted a write up of CVM (Cel-Sci Corp) on the SH Bull board that nobody follows. Already a multi-bagger and if they get FDA ph 3 approval near term, it will probably reach an exponential stock price. Do your own DD and good luck and congrats to longs here as well.

Bullboard Posts

3 Mid-Sized Stocks to Consider This Season